Intravenous omeprazole prevents rebleeding in peptic ulcer patients with a non-bleeding visible vessel: A preliminary report of a randomized controlled study

Rudy Tan Chua, Hwai Jeng Lin, Kun Wang, Chin Lin Perng, Wen Chin Lo, Chen Hsen Lee, Shou Dong Lee

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background. In patients with peptic ulcer bleeding, acid can enhance platelet disaggregation and cause lysis of the clot. Omeprazole, a potent acid suppressor, may be helpful in reducing their rebleeding rate. Methods. Between March and October 1994, 40 patients with a non-bleeding, visible vessel (NBVV) at ulcer bases were enrolled for study. They were randomized into four groups. Group I (n = 10) patients received cimetidine 300 mg intravenously (i.v.) q6h; Group II (n = 10) patients received heater probe thermocoagulation therapy and cimetidine 300 mg i.v. q6h; Group III (n = 10) patients received omeprazole 40 mg intravenous bolus initially followed by 40 mg i.v. qd and Group IV (n = 10) patients received omeprazole 40 mg intravenous bolus initially followed by 40 mg i.v. q12h. Endoscopic examination was done for follow-up, daily, for 1-3 days. Results. Preliminary results showed that the age, initial hemoglobin, ulcer size as well as NBVV size in Groups I-IV were not significantly different (p <0.05). The rebleeding rates were 40% in Group I, 20% in Group II, 20% in Group III and 0% in Group IV. (p <0.05 when Group IV is compared with Group I). Conclusions. Intravenous omeprazole 40 mg given q12h can reduce the rebleeding rate of patients with a NBVV.

Original languageEnglish
Pages (from-to)139-145
Number of pages7
JournalChinese Medical Journal (Taipei)
Volume57
Issue number2
Publication statusPublished - Feb 1996
Externally publishedYes

Fingerprint

Omeprazole
Peptic Ulcer
Cimetidine
Ulcer
Electrocoagulation
Acids
Hemoglobins
Blood Platelets
Hemorrhage

Keywords

  • non-bleeding visible vessel
  • omeprazole
  • peptic ulcer

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Intravenous omeprazole prevents rebleeding in peptic ulcer patients with a non-bleeding visible vessel : A preliminary report of a randomized controlled study. / Chua, Rudy Tan; Lin, Hwai Jeng; Wang, Kun; Perng, Chin Lin; Lo, Wen Chin; Lee, Chen Hsen; Lee, Shou Dong.

In: Chinese Medical Journal (Taipei), Vol. 57, No. 2, 02.1996, p. 139-145.

Research output: Contribution to journalArticle

Chua, Rudy Tan ; Lin, Hwai Jeng ; Wang, Kun ; Perng, Chin Lin ; Lo, Wen Chin ; Lee, Chen Hsen ; Lee, Shou Dong. / Intravenous omeprazole prevents rebleeding in peptic ulcer patients with a non-bleeding visible vessel : A preliminary report of a randomized controlled study. In: Chinese Medical Journal (Taipei). 1996 ; Vol. 57, No. 2. pp. 139-145.
@article{7a4e8156e63a43a79feff94cea6d96de,
title = "Intravenous omeprazole prevents rebleeding in peptic ulcer patients with a non-bleeding visible vessel: A preliminary report of a randomized controlled study",
abstract = "Background. In patients with peptic ulcer bleeding, acid can enhance platelet disaggregation and cause lysis of the clot. Omeprazole, a potent acid suppressor, may be helpful in reducing their rebleeding rate. Methods. Between March and October 1994, 40 patients with a non-bleeding, visible vessel (NBVV) at ulcer bases were enrolled for study. They were randomized into four groups. Group I (n = 10) patients received cimetidine 300 mg intravenously (i.v.) q6h; Group II (n = 10) patients received heater probe thermocoagulation therapy and cimetidine 300 mg i.v. q6h; Group III (n = 10) patients received omeprazole 40 mg intravenous bolus initially followed by 40 mg i.v. qd and Group IV (n = 10) patients received omeprazole 40 mg intravenous bolus initially followed by 40 mg i.v. q12h. Endoscopic examination was done for follow-up, daily, for 1-3 days. Results. Preliminary results showed that the age, initial hemoglobin, ulcer size as well as NBVV size in Groups I-IV were not significantly different (p <0.05). The rebleeding rates were 40{\%} in Group I, 20{\%} in Group II, 20{\%} in Group III and 0{\%} in Group IV. (p <0.05 when Group IV is compared with Group I). Conclusions. Intravenous omeprazole 40 mg given q12h can reduce the rebleeding rate of patients with a NBVV.",
keywords = "non-bleeding visible vessel, omeprazole, peptic ulcer",
author = "Chua, {Rudy Tan} and Lin, {Hwai Jeng} and Kun Wang and Perng, {Chin Lin} and Lo, {Wen Chin} and Lee, {Chen Hsen} and Lee, {Shou Dong}",
year = "1996",
month = "2",
language = "English",
volume = "57",
pages = "139--145",
journal = "Journal of the Chinese Medical Association",
issn = "1726-4901",
publisher = "Elsevier Taiwan LLC",
number = "2",

}

TY - JOUR

T1 - Intravenous omeprazole prevents rebleeding in peptic ulcer patients with a non-bleeding visible vessel

T2 - A preliminary report of a randomized controlled study

AU - Chua, Rudy Tan

AU - Lin, Hwai Jeng

AU - Wang, Kun

AU - Perng, Chin Lin

AU - Lo, Wen Chin

AU - Lee, Chen Hsen

AU - Lee, Shou Dong

PY - 1996/2

Y1 - 1996/2

N2 - Background. In patients with peptic ulcer bleeding, acid can enhance platelet disaggregation and cause lysis of the clot. Omeprazole, a potent acid suppressor, may be helpful in reducing their rebleeding rate. Methods. Between March and October 1994, 40 patients with a non-bleeding, visible vessel (NBVV) at ulcer bases were enrolled for study. They were randomized into four groups. Group I (n = 10) patients received cimetidine 300 mg intravenously (i.v.) q6h; Group II (n = 10) patients received heater probe thermocoagulation therapy and cimetidine 300 mg i.v. q6h; Group III (n = 10) patients received omeprazole 40 mg intravenous bolus initially followed by 40 mg i.v. qd and Group IV (n = 10) patients received omeprazole 40 mg intravenous bolus initially followed by 40 mg i.v. q12h. Endoscopic examination was done for follow-up, daily, for 1-3 days. Results. Preliminary results showed that the age, initial hemoglobin, ulcer size as well as NBVV size in Groups I-IV were not significantly different (p <0.05). The rebleeding rates were 40% in Group I, 20% in Group II, 20% in Group III and 0% in Group IV. (p <0.05 when Group IV is compared with Group I). Conclusions. Intravenous omeprazole 40 mg given q12h can reduce the rebleeding rate of patients with a NBVV.

AB - Background. In patients with peptic ulcer bleeding, acid can enhance platelet disaggregation and cause lysis of the clot. Omeprazole, a potent acid suppressor, may be helpful in reducing their rebleeding rate. Methods. Between March and October 1994, 40 patients with a non-bleeding, visible vessel (NBVV) at ulcer bases were enrolled for study. They were randomized into four groups. Group I (n = 10) patients received cimetidine 300 mg intravenously (i.v.) q6h; Group II (n = 10) patients received heater probe thermocoagulation therapy and cimetidine 300 mg i.v. q6h; Group III (n = 10) patients received omeprazole 40 mg intravenous bolus initially followed by 40 mg i.v. qd and Group IV (n = 10) patients received omeprazole 40 mg intravenous bolus initially followed by 40 mg i.v. q12h. Endoscopic examination was done for follow-up, daily, for 1-3 days. Results. Preliminary results showed that the age, initial hemoglobin, ulcer size as well as NBVV size in Groups I-IV were not significantly different (p <0.05). The rebleeding rates were 40% in Group I, 20% in Group II, 20% in Group III and 0% in Group IV. (p <0.05 when Group IV is compared with Group I). Conclusions. Intravenous omeprazole 40 mg given q12h can reduce the rebleeding rate of patients with a NBVV.

KW - non-bleeding visible vessel

KW - omeprazole

KW - peptic ulcer

UR - http://www.scopus.com/inward/record.url?scp=0029964102&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029964102&partnerID=8YFLogxK

M3 - Article

C2 - 8634929

AN - SCOPUS:0029964102

VL - 57

SP - 139

EP - 145

JO - Journal of the Chinese Medical Association

JF - Journal of the Chinese Medical Association

SN - 1726-4901

IS - 2

ER -